The Life Sciences CLE Week sessions include:

Rule 702 – Don’t Say Daubert | Monday, November 8, 12-1 PM ET | This session examines the amendments to F.R. Evid. 702 recently proposed by the Civil Rules Committee of the Federal Courts. In addition to explaining what the amendments are intended to do, we will discuss the problems that led the committee to conclude that amendments were necessary. The session will also describe how these amendments are helpful to defendants in prescription medical product liability litigation, and what defendants and their counsel can do to help get them enacted.

Tales from the Trenches: Lessons Learned from Two Trial Victories During the Pandemic | Rescheduled to Tuesday, December 14 | 3-4 PM ET | Two of Reed Smith’s product liability trial teams recently won defense verdicts for their life sciences clients. In this session, trial team members will reflect on key lessons learned while litigating in person during the pandemic, and offer takeaways life sciences companies can apply in both their current and post-pandemic product litigation appearances.

Biometrics: What Life Sciences and Digital Health Companies Need to Know About the Evolving Litigation and Regulatory Landscape | Tuesday, November 9, 3-4 PM ET | Currently, companies must navigate a patchwork of U.S. state and municipal biometric laws that govern the collection and use of biometric data. One such statute provides for a private right of action, significant statutory awards – reflecting thousands of dollars per violation – and is considered "ready-made" for class action treatment. Our presenters will discuss how you can best protect yourselves from significant exposure with limited defenses to many of these laws.

Health Care Fraud and Abuse in a Digital World | Wednesday, November 10, 1-2 PM ET | This session will cover nuanced health care fraud and abuse and privacy risks associated with the development of, and investment in, health information technology tools, build guides, and resources. This session will be geared towards drug and device manufacturers and technology companies and will provide attendees with an understanding of what constitutes health information technology; how the federal anti-kickback statute, the federal false claims act, HIPAA and other laws apply in the digital world; and best practices for compliance.

Artificial Intelligence, Intellectual Property and the Life Sciences Industry – What Next? | Thursday, November 11 | 12:30-1:30 PM ET | Companies are increasingly using smart systems for a variety of applications, including assistance with drug discovery and pharmaceutical and medicinal product development. In the wake of the U.S., European, and Australian decisions regarding the DABUS “creativity machine” and its inventions, questions relating to the protection of AI-generated work products are gaining more prominence. This session will provide an update on recent developments, including whether AI systems can conceive of inventions, who can apply for patent protection, and who should be designated as the inventor.

CLE: Each webinar is presumptively approved for 1.0 CLE credit in California, Connecticut, Illinois, New Jersey, New York, Pennsylvania, Texas and West Virginia. Applications for CLE credit will be filed in Delaware, Florida, Ohio, and Virginia. Attendees who are licensed in other jurisdictions will receive a uniform certificate of attendance but Reed Smith only provides credit for the states listed. Please allow 4-6 weeks after the program to receive a certificate of attendance.